Breast Cancer Therapeutics Market Size expected to witness growth to surpass USD 16 billion by 2023. Breast Cancer Therapeutics Market size was valued at over USD 7.5 billion in 2015 and is expected to witness growth to surpass USD 16 billion by 2023. China breast cancer therapeutics market share accounted for over 15% of the Asia Pacific revenue. Australia accounted for over 10% and India contributed 3% to overall revenue generation, with the latter expected to grow at 9% CAGR over the forecast timeframe. According to WHO statistics, it is the second most prevalent type of the disease globally, and the most widespread type in females. In women, it accounts for 20% of all invasive and 13% of all female cancers, and is responsible for 15% of all deaths caused by the disease globally, including both females and males. Every year, around 200,000 new cases in women and nearly 2,000 new cases in men are diagnosed.
This disease occurs when cells in the breast show uncontrolled growth. Malignant tumors may metastatize or growing into the surrounding tissues. It generally either begins in the lobules, which are the milk producing glands, or the inner lining of ducts, the passage that supply milk from lobules. Tumor occurring in the lobules is lobular carcinoma which represents 80% to 90% of all cases, while one which develops from the ducts is ductal carcinoma, representing 10% to 20% of all cases. In developed countries, the rates are much higher compared to their developing counterparts. However, in many developing nations, it is now rising abruptly due to changes in lifestyle, reproductive factors, and increased life expectancy. Mortality from breast cancer is a leading cause of death among women in developing countries, as well as in the developed world. Approximately 85% to 90% of all cases are caused by genetic abnormality, while the remaining are due to inherited abnormalities. High degree of competition, potential side effects, growing number of medication options, and substitute branded drugs availability may adversely impact revenue in the coming years. On the basis of drug class, the industry is categorized into five major segments, namely, anti-metabolites, HER2 inhibitors, aromatase inhibitors, mitotic inhibitors, and hormone receptors. 1|Page